Harvard Management CO Inc Gemini Therapeutics, Inc. Transaction History

Harvard Management CO Inc

  • $1.73 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 07, 2021
BUY
$11.32 - $18.0 $2.83 Million - $4.5 Million
250,000 New
250,000 $3.39 Million

Others Institutions Holding GMTX

# of Institutions
1
Shares Held
2.44M
Call Options Held
0
Put Options Held
0
View Full List

About Gemini Therapeutics, Inc.

GMTX Quotes by TradingView
  • Ticker GMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,244,500
  • Market Cap $1.05B
  • Description
  • Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...
More about GMTX
Track This Portfolio

Track Harvard Management CO Inc Portfolio

Follow Harvard Management CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harvard Management CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Harvard Management CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email